Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways

OBJECTIVE: Pancreatic cancer is one of the most lethal types of cancer with a 5-year survival rate of ~5%. Histone deacetylases (HDACs) participate in many cellular processes, including carcinogenesis, and pharmacological inhibition of HDACs has emerged as a potential therapeutic strategy. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Jin, Wang, Wen-Hung, Wu, Wan-Yu, Hsu, Chia-Chi, Wei, Ling-Rung, Wang, Sheng-Fan, Hsu, Ya-Wen, Liaw, Chih-Chuang, Tsai, Wan-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567660/
https://www.ncbi.nlm.nih.gov/pubmed/28829799
http://dx.doi.org/10.1371/journal.pone.0183368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567660/
https://www.ncbi.nlm.nih.gov/pubmed/28829799
http://dx.doi.org/10.1371/journal.pone.0183368

Ejemplares similares